<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2009</study_start_year><condition>Rectal Neoplasms</condition><condition>Cancer-Bowel-Back passage (rectum) or large bowel (colon)</condition><condition>Rectal Cancer</condition><condition>Locally Advanced Rectal Cancer</condition><disease>Rectal Neoplasms</disease><disease>Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)</disease><disease>Rectal Cancer</disease><disease>Locally Advanced Rectal Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2080802</full_dataset_link><location>Australia</location><study_start_month>11</study_start_month><keyword>Chemotherapy</keyword><keyword>Oxaliplatin</keyword><keyword>Leucovorin</keyword><keyword>Radiotherapy</keyword><keyword>Fluorouracil</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer</name><description>The aims of the trial are (1) to determine the tolerability rate in the setting of a multi-centre study and (2) to determine secondary tolerability endpoints, toxicity rates and complete pathologic response rate in patients with locally advanced rectal cancer who are treated with an integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.</description><dates><creation>2009-11-15</creation></dates><accession>2080802</accession><cross_references><ClinicalTrials___gov>NCT01013805</ClinicalTrials___gov><Australian New Zealand Clinical Trials Registry>ACTRN12610000175077</Australian New Zealand Clinical Trials Registry></cross_references></HashMap>